MediciNova Secures European Patent for MN-166 Plus Riluzole

MediciNova Secures European Patent for MN-166 Plus Riluzole

294194

MediciNova Secures European Patent for MN-166 Plus Riluzole

The European Patent Office will grant MediciNova a patent that covers the combination of MN-166 (ibudilast) and riluzole for the treatment of amyotrophic lateral sclerosis (ALS), MediciNova announced. The patent, once issued, will cover a wide range of doses and dosing regimens for both medications, and it is expected to be in effect until at least November 2035. MediciNova has received similar patents in the U.S. and Japan. “We are very pleased to receive notice…

You must be logged in to read/download the full post.